{"id":915445,"date":"2025-12-02T16:59:52","date_gmt":"2025-12-02T21:59:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/"},"modified":"2025-12-02T16:59:52","modified_gmt":"2025-12-02T21:59:52","slug":"zymeworks-announces-participation-in-upcoming-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/","title":{"rendered":"Zymeworks Announces Participation in Upcoming Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\u2022 <em>Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera<\/em><em>\u00ae<\/em><em> across HER2-driven gastrointestinal cancers by partner Jazz<\/em><\/p>\n<p align=\"center\">\u2022 <em>Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI<\/em><\/p>\n<p align=\"center\">\u2022 <em>Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT)<\/em><\/p>\n<p>VANCOUVER, British Columbia, Dec.  02, 2025  (GLOBE NEWSWIRE) &#8212; Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced participation in the following upcoming conferences.<\/p>\n<p>\n        <strong>ASCO Gastrointestinal Cancers Symposium<br \/><\/strong>January 8-10, 2026<br \/>San Francisco, CA<\/p>\n<p>\n        <em>Zymeworks Presentation<\/em>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:33%;width:33%;min-width:33%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Presentation Title<\/strong>\n          <\/td>\n<td style=\"max-width:34%;width:34%;min-width:34%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Authors<\/strong>\n          <\/td>\n<td style=\"max-width:33%;width:33%;min-width:33%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Presentation Details<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ZW251 \u2014A Phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC).<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">Sreenivasa Chandana, Robin Kate Kelley, Richard Finn, Ecaterina E. Dumbrava, Masafumi Ikeda, John Hamm, Jaspreet Grewal, Martin Gutierrez, Yuta Maruki, Takako Eguchi Nakajima, Tatsuki Ikoma, Maggie Weinstein, Sabeen Mekan, Ghassan K.Abou-Alfa<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Type: <\/strong>Trials in Progress Poster Session<\/p>\n<p><strong>Session: <\/strong>Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract<\/p>\n<p><strong>Date: <\/strong>Friday, Jan. 9, 11:30 am \u2013 1:00 pm PT<\/p>\n<p><strong>Abstract number: <\/strong>TPS608<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <em>Partner Presentations<\/em>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:33%;width:33%;min-width:33%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Presentation Title<\/strong>\n          <\/td>\n<td style=\"max-width:34%;width:34%;min-width:34%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Authors<\/strong>\n          <\/td>\n<td style=\"max-width:33%;width:33%;min-width:33%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Presentation Details<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Zanidatamab (zani) + chemotherapy (chemo) \u00b1 tislelizumab (tisle) for first-line (1L) HER2-positive (HER2+)<br \/>advanced\/metastatic gastroesophageal adenocarcinoma (mGEA): first results from the phase 3 HERIZON-GEA-01\u00a0study<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">Elena Elimova, Sun Young Rha, Kohei Shitara, Tianshu Liu, Josep Tabernero, Keun-Wook Lee, Michael Schenker, Niall Tebbutt, Jaffer Ajani, Norhidayu Bt Salimin, Geoffrey Ku, Jong Gwang Kim, Inmaculada Ales Diaz, Jingdong Zhang, Filippo Pietrantonio, Li-Yuan Bai, Samuel Le Sourd, Ye Chen, Jonathan Grim, Lin Shen, on behalf of the HERIZON-GEA-01 study group<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Type: <\/strong>Late-Breaking Abstract Oral Presentation<\/p>\n<p><strong>Session:\u00a0<\/strong>Oral Abstract Session A: Cancers of the Esophagus and Stomach<\/p>\n<p><strong>Date: <\/strong>Thursday, Jan. 8, 8:57 \u2013 9:07 am PT<\/p>\n<p><strong>Abstract number: <\/strong>LBA285<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Landmark analysis of overall survival (OS) by objective response in patients (pts) with previously treated, advanced HER2-positive biliary tract cancer (BTC): post hoc analysis of the HERIZON-BTC-01\u00a0trial<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">James J Harding, Jia Fan, Do-Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui-Chuan Sun, Teresa Macarulla, Feng Xie, Jean-Philippe Metges, Jie\u2019er Ying, John Bridgewater, Harpreet Singh Wasan, Michel Pierre Ducreux, Zinan Bao, Phillip M Garfin, Douglas S Fuller, Parveen Jayia, Shubham Pant<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Type: <\/strong>Poster Session<\/p>\n<p><strong>Session: <\/strong>Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract<\/p>\n<p><strong>Date: <\/strong>Friday, Jan. 9, 11:30 am \u2013 1:00 pm PT<\/p>\n<p><strong>Abstract number: <\/strong>545<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>The majority of abstracts accepted to ASCO GI will be released at 2:00 pm PT\/ 5:00 pm Eastern Time (ET) on January 5, 2026. Late-breaking abstracts will be released at 7:00 am PT \/ 10:00 am ET on their day of presentation at the Symposium and made publicly available online at that time.<\/p>\n<p>\n        <strong>J.P. Morgan Annual Healthcare Conference<br \/><\/strong>January 12-16, 2026<br \/>San Francisco, CA<\/p>\n<p>Zymeworks\u2019 management will participate in one-on-one meetings and a corporate presentation on January 14, 2026, at 3:00 pm PT.<\/p>\n<p>\n        <strong>About Zymeworks Inc.<\/strong>\n      <\/p>\n<p>Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company\u2019s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera\u00ae (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera\u00ae (zanidatamab-hrii), a HER2-targeted bispecific antibody using the Company\u2019s proprietary Azymetric\u2122 technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company\u2019s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=whKkBO2YECAEee_zE0ntOhHq5YYRzaYJH1BlIyW6PfLG_on6U4MMjtwJGiQdg-HcoiC06XDEaOfvQW4LxgpafBAnN6oBWUb1CaR3EevMQQc=\" rel=\"nofollow\" target=\"_blank\">www.zymeworks.com<\/a> and follow @ZymeworksInc on X.<\/p>\n<p>\n        <strong>Investor inquiries:<\/strong>\n      <\/p>\n<p>Shrinal Inamdar<br \/>Senior Director, Investor Relations<br \/>(604) 678-1388<br \/>ir@zymeworks.com<\/p>\n<p>\n        <strong>Media inquiries:<\/strong>\n      <\/p>\n<p>Diana Papove<br \/>Senior Director, Corporate Communications <br \/>(604) 678-1388<br \/>media@zymeworks.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU4MiM3MzAyMTcwIzIyNTY4OTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGY3Yzg1NzMtNzliMi00NzViLTgxMjgtYTRjZmEwNjRmMzA5LTEyNjg0NDItMjAyNS0xMi0wMi1lbg==\/tiny\/Zymeworks-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2022 Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera\u00ae across HER2-driven gastrointestinal cancers by partner Jazz \u2022 Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI \u2022 Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT) VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) &#8212; Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced participation in the following upcoming conferences. ASCO Gastrointestinal Cancers SymposiumJanuary 8-10, 2026San Francisco, CA Zymeworks Presentation Presentation Title Authors Presentation Details ZW251 \u2014A Phase 1, first-in-human, multicenter study &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zymeworks Announces Participation in Upcoming Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915445","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zymeworks Announces Participation in Upcoming Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zymeworks Announces Participation in Upcoming Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2022 Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera\u00ae across HER2-driven gastrointestinal cancers by partner Jazz \u2022 Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI \u2022 Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT) VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) &#8212; Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced participation in the following upcoming conferences. ASCO Gastrointestinal Cancers SymposiumJanuary 8-10, 2026San Francisco, CA Zymeworks Presentation Presentation Title Authors Presentation Details ZW251 \u2014A Phase 1, first-in-human, multicenter study &hellip; Continue reading &quot;Zymeworks Announces Participation in Upcoming Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T21:59:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU4MiM3MzAyMTcwIzIyNTY4OTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zymeworks Announces Participation in Upcoming Conferences\",\"datePublished\":\"2025-12-02T21:59:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/\"},\"wordCount\":737,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTU4MiM3MzAyMTcwIzIyNTY4OTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/\",\"name\":\"Zymeworks Announces Participation in Upcoming Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTU4MiM3MzAyMTcwIzIyNTY4OTM=\",\"datePublished\":\"2025-12-02T21:59:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTU4MiM3MzAyMTcwIzIyNTY4OTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTU4MiM3MzAyMTcwIzIyNTY4OTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zymeworks Announces Participation in Upcoming Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zymeworks Announces Participation in Upcoming Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Zymeworks Announces Participation in Upcoming Conferences - Market Newsdesk","og_description":"\u2022 Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera\u00ae across HER2-driven gastrointestinal cancers by partner Jazz \u2022 Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI \u2022 Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT) VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) &#8212; Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced participation in the following upcoming conferences. ASCO Gastrointestinal Cancers SymposiumJanuary 8-10, 2026San Francisco, CA Zymeworks Presentation Presentation Title Authors Presentation Details ZW251 \u2014A Phase 1, first-in-human, multicenter study &hellip; Continue reading \"Zymeworks Announces Participation in Upcoming Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-02T21:59:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU4MiM3MzAyMTcwIzIyNTY4OTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zymeworks Announces Participation in Upcoming Conferences","datePublished":"2025-12-02T21:59:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/"},"wordCount":737,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU4MiM3MzAyMTcwIzIyNTY4OTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/","name":"Zymeworks Announces Participation in Upcoming Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU4MiM3MzAyMTcwIzIyNTY4OTM=","datePublished":"2025-12-02T21:59:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU4MiM3MzAyMTcwIzIyNTY4OTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU4MiM3MzAyMTcwIzIyNTY4OTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zymeworks Announces Participation in Upcoming Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915445"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915445\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}